Westlake Corporation

Westlake is a vertically integrated North American and European materials group. Its chain starts with ethane- and salt-based feedstocks and runs through ethylene and chlor-alkali into PVC, polyethylene, epoxy and caustic soda. It then converts a large share of its own PVC into branded building products and PVC pipe, fittings and compounds.

This "molecule-to-house" integration is unusual among U.S. petrochemical producers. The Housing and Infrastructure Products (HIP) segment provides relatively stable, high-margin cash flow, with a 20% EBITDA margin in FY2025. The Performance and Essential Materials (PEM) segment provides high operating leverage to the global commodity cycle.

FY2025 was a trough year: a GAAP net loss of $1.5bn after a $727M goodwill impairment and four plant closures. Management has since pivoted to a self-help programme, the "three-pillar" plan targeting ~$600M of 2026 EBITDA uplift. That plan, together with a Middle-East-driven steepening of the global cost curve, returned the company to profit in Q2 2026. Westlake is family-controlled and investment-grade rated, with a 22-year record of annual dividend increases.

Company's own description (paraphrased from 10-K FY2025, Item 1)

Westlake describes itself as a vertically integrated global manufacturer and marketer of housing and infrastructure products and of performance and essential materials. Its materials serve residential construction, flexible and rigid packaging, automotive, healthcare, water treatment, wind turbines, coatings and other durable and non-durable goods.

It reports two operating segments, HIP and PEM. It emphasises two layers of integration:

Upstream to midstream: ethylene and chlor-alkali (chlorine and caustic soda) feed vinyls, polyethylene and epoxy.

Midstream to downstream: PVC feeds residential building products, PVC pipe and fittings, and PVC compounds in HIP.

Independent characterization

Economically, Westlake is two businesses sharing one balance sheet.

PEM is a global-scale, cost-advantaged commodity producer. At 18 Feb 2026 it had ~39.2bn lb/yr of aggregate production capacity (10-K FY2025). Its competitive edge comes from:

• U.S. Gulf Coast ethane feedstock;

• captive ethylene through OpCo (Westlake Chemical Partners) and a 50% interest in the LACC cracker;

• self-sufficiency in chlorine;

• owned salt domes and on-site cogeneration at Lake Charles (~790 MW), Plaquemine (~240 MW) and Natrium (~100 MW).

PEM earnings swing on global supply and demand for PVC, caustic soda and polyethylene. They also swing on the oil-to-gas spread that sets the global cost curve. PEM EBITDA excluding identified items was only $267M in FY2025 but $416M in Q2 2026 alone.

HIP is a branded, distribution-heavy building-products and water-infrastructure business. It runs 53 manufacturing facilities, primarily in North America, plus 11 compounds plants globally. Its EBITDA margins have been 19–25% since FY2023, and its earnings are driven by:

• U.S. repair-and-remodel activity;

• new residential construction;

• municipal water and sewer spending.

Roughly 60–70% of its PVC input is sourced internally from PEM, which keeps value-chain margin inside the group.

Revenue model

Westlake is almost entirely a product-sale business. Licensing exists but is immaterial: the company says it licenses internally developed technology "when the opportunity makes sense." There is no subscription or service revenue of note.

PEM sells:

• under contracts priced monthly against benchmarks (with lags);

• on spot and export markets;

• through ethylene co-product sales via OpCo, including propylene, crude butadiene, pyrolysis gasoline and hydrogen.

HIP sells:

• through an internal sales force and manufacturers' representatives to distributors, dealers, contractors, builders and municipal water and sewer channels;

• supported by 47 North American distribution centres and warehouses (39 leased, 8 owned).

No single customer accounted for ≥10% of either segment's net sales in FY2025 (10-K FY2025).

Stated strategy themes (10-K FY2025, paraphrased)

• Deliver value to customers, create sustainable shareholder value and develop a rewarding workplace.

• Maintain high customer service and operational excellence with disciplined cost management.

• Pursue external and internal growth that complements the integrated structure.

• Optimise the asset footprint and productivity.

• Prioritise sustainability: recycling, waste reduction, recycled content, renewable and bio-based inputs, and durable and efficient products.

Three-pillar profitability improvement plan (announced Dec 2025)

Most of the uplift is expected to benefit PEM. The Q2 2026 release describes the target as a $600M operating income benefit.

PEM: Performance Materials and Essential Materials (capacity at 18 Feb 2026, 10-K FY2025)

*Cologne PVC (~165kt ≈ 364M lb) is to close in Q1 2027. Wilhelmshaven (380kt PVC plus VCM) was acquired in June 2026 and is not included in the 18 Feb 2026 capacity figures.

Named chlorinated-derivative products: ethyl chloride, perchloroethylene, trichloroethylene, tri-ethane® solvents, VersaTRANS® solvents, calcium hypochlorite, hydrochloric acid, pelletized caustic soda.

Ethylene co-products (via OpCo): chemical-grade propylene, crude butadiene, pyrolysis gasoline, hydrogen.

Pricing model. Commodity contract pricing typically resets monthly, often with lags; spot and export sales track global benchmarks. HIP pricing is list or programme pricing through distribution. Specific price lists are not publicly disclosed.

All figures are USD M from 10-K filings (FY2021–FY2025), extracted via SEC XBRL (edgar.tools), unless noted. EBITDA follows the company's definition: income from operations + depreciation & amortization + other income, net. It is derived here on a GAAP basis, including identified items.

Income statement

Notes on this table:

• FY2021 interest expense is derived from operating income + other income − pre-tax income.

• Diluted EPS for FY2021–FY2023 is per the respective 10-Ks (analyst-recalled; verify). FY2024–FY2025 EPS is per 10-K FY2025.

• Basic EPS: FY2025 basic equals diluted (−11.70), because loss years are anti-dilutive. Earlier basic EPS was within ~$0.10 of diluted (n.d. precisely here).

• Reported FY2024 EBITDA excl. items was "$2.3bn"; FY2025 was "$1.1bn" (rounded).

Margins and growth

Revenue CAGR FY2021–FY2025: −1.3% per year (11,778 to 11,170, derived). FY2022 was the cyclical peak, so FY2022–FY2025 CAGR is −10.9%.

Commentary.

FY2021–FY2022 (peak): Post-COVID restocking, Winter Storm Uri supply losses and tight global PVC and caustic markets drove record pricing. The Boral (Oct 2021) and Hexion epoxy (Feb 2022) acquisitions inflated FY2022 sales and SG&A. SG&A jumped from $551M to $835M as building-products businesses carry structurally higher SG&A.

FY2023 (inflection down): PEM pricing collapsed as Chinese PVC and caustic exports and new Gulf Coast PE capacity hit global markets. Gross margin fell ~8 points. The $475M impairment followed European asset actions.

FY2024 (stabilisation): Sales volume grew for five consecutive quarters, and HIP set a record operating income of $807M. However, PEM prices kept falling, and a $45M one-off Louisiana tax charge plus $75M of shutdown accruals held net income to $602M.

FY2025 (trough): The full-year adjusted net loss was $116M, with $1.1bn of adjusted EBITDA. Drivers were:

• a 5% volume decline and 3% lower average price;

• higher feedstock and energy costs;

• an elevated level of planned and unplanned outages. GAAP results were further burdened by a $727M goodwill impairment and $640M of restructuring and closure costs: Pernis $247M, North American chlorovinyls and styrene $393M, Huasu $9M, and HIP restructuring.

H1 2026 (recovery): Q2 2026 net income was $260M (diluted EPS $2.01) on $3.27bn of sales, and EBITDA was $679M at a 21% margin. Drivers were a 14% YoY PEM price increase linked to Strait of Hormuz disruption, ~$150M per quarter of three-pillar benefits, and ACI. Management guided Q3 2026 sequentially lower as NA PVC and PE prices moderated (29 Sep 2026 release).

Balance sheet (31 December)

Latest interim balance sheet (30 Jun 2026, Q2 2026 release):

• Cash $1,643M plus AFS securities $209M = $1.85bn liquidity in cash and investments.

• Total debt $5,067M (no current portion after the 2026 notes were redeemed).

• Implied net debt ~$3.2bn (derived).

• Westlake equity $8,705M; total assets $19,439M.

Commentary.

• Net debt nearly doubled in FY2025 as operating cash flow (OCF) fell to $465M while capex stayed at ~$1bn.

• Q1 2026 working-capital build, the ACI purchase ($171M net) and the $496M redemption of the 3.60% 2026 notes cut cash by ~$1.1bn in H1 2026.

• Goodwill fell 35% after the chlorovinyls impairment. Remaining goodwill is concentrated in HIP (Boral / LASCO / Dimex) and epoxy.

Cash flow

H1 2026:

• OCF $224M; capex $416M; FCF −$192M.

• Q2 2026 FCF was +$111M.

• Dividends $137M; buybacks $30M; acquisitions $171M.

• FY2026 capex guidance is ~$900M (Q4 2025 call).

Ratios (analyst-derived from reported figures; year-end balances)

Latest twelve months (Q3 2025–Q2 2026, derived):

• Net sales $11,294M; EBITDA excl. items $1,423M (313 + 196 + 235 + 679).

• Net debt / LTM adjusted EBITDA ≈ 2.3x.

• Adjusted LTM diluted EPS ≈ $0.70 (−0.29 − 0.25 − 0.77 + 2.01).

• GAAP LTM net loss ≈ −$1,235M.

Commentary. Returns compressed from mid-teens ROIC at the 2021–22 peak to low single digits in 2023–24. They turned negative in 2025 on impairments. Leverage remains moderate by chemical-sector standards: management stresses an investment-grade balance sheet. However, 2.3x net debt / LTM EBITDA is the highest since the Axiall integration period. The cash conversion cycle has lengthened by ~5 days since FY2024, reflecting receivables growth.

Management guidance (latest)

FY2026 HIP: revenue $4.4–4.6bn at a 19–21% EBITDA margin. H1 2026 HIP sales were $2.25bn with a 21% EBITDA margin excluding items.

Self-help: ~$600M of 2026 EBITDA uplift; ~$300M recognised in H1 2026.

Capex: ~$900M.

Q3 2026: sequentially lower than Q2 because NA PVC and PE prices moderated, freight costs rose and housing softened.

Cologne: ~$110M of closure charges in 2026.

Consensus expectations (indicative)

• In February 2026, consensus projected FY2026 EBITDA of ~$1.58bn (+38% YoY) and normalized EPS of ~$1.39 (TIKR summary).

• H1 2026 adjusted EBITDA was $914M and adjusted EPS $1.24. With Q3 guided down, full-year outcomes around consensus EBITDA appear plausible but depend on Q4 PEM pricing.

Bull case

1. Self-help is structural. About $400M of the $600M (footprint plus cost) does not depend on the cycle. Combined with HIP's ~$0.85–0.95bn EBITDA base, normalized EBITDA could exceed $2bn on any PEM recovery, against an ~$11.8bn EV.

2. Lower-cost footprint. Westlake has removed roughly 1bn lb of PVC, 1.8bn lb of VCM, 825M lb of chlorine and its styrene and Pernis epoxy assets. Combined with Wilhelmshaven, this leaves it with a lower-cost footprint just as Chinese export rebates were removed and Middle East disruption steepened the cost curve. Q2 2026 showed the operating leverage: PEM EBITDA margin jumped from 2% to 21% in one quarter.

3. Asset-value support. The stock trades below book value (~0.9x P/B) with an investment-grade balance sheet, long-dated debt and a 22-year dividend record. The Dutch ethylene rulings and the $67M PVC-pipe settlement reduce legal tail risk.

Bear case

1. Overcapacity. Global PE and chlorovinyl overcapacity persists. The Q2 2026 price spike was geopolitical and is already reversing (Q3 guided lower, Cologne closure). PEM could revert to the low-single-digit margins of 2025 (3.8%).

2. HIP pressure. HIP faces slower housing on affordability, raw-material and freight inflation, and HIP average sales price down 3% YoY in Q2 2026. Its margin compressed from 24% to 22%, and 2026 guidance risks the lower end.

3. Weak cash conversion. FCF was −$530M in FY2025 and −$192M in H1 2026. Repeated closure charges (more than $1bn since 2023) and a step-up in environmental capex ($103–125M per year) could keep leverage above 2x. Controlled-company status caps re-rating potential.

Concluding analyst verdict

Westlake enters late 2026 as a business in transition from a deep cyclical trough to an uncertain recovery. Its strategic logic is intact. The integration of low-cost U.S. Gulf Coast ethylene and chlor-alkali into PVC, and of PVC into branded building products and water infrastructure, remains among the most defensible configurations in North American chemicals. HIP's ability to hold roughly 20% EBITDA margins through the 2025 downturn proves the value of that downstream anchor.

The weakness lies in PEM's exposure to a structurally oversupplied global market. That exposure forced more than $1.1bn of closure costs and a $727M goodwill write-off in 2025, and has now prompted the Cologne exit.

Management under Jean-Marc Gilson has responded with unusual decisiveness for a family-controlled company. It shut sub-scale assets, delivered $170M of cost savings and pursued tuck-in, distressed-price acquisitions (ACI, Wilhelmshaven). The roughly $150M per quarter of realised self-help in H1 2026 is credible evidence of execution.

However, the Q2 2026 rebound owed much to the Strait of Hormuz disruption, and the guidance for a weaker Q3 confirms how quickly that tailwind fades. On our derived metrics, the shares trade at about 8x LTM adjusted EBITDA, below book value, with a 3.4% dividend yield. That valuation already discounts a muted PEM environment. Upside requires either sustained cost-curve support or evidence that the footprint reset has permanently lifted PEM's trough margin.

Our synthesis is balanced to modestly constructive over a 12–24 month horizon, contingent on three conditions:

1. full delivery of the $600M plan;

2. HIP margins holding at or above 19%;

3. no adverse reversal in the European ethylene litigation.

Investors should size positions for continued earnings volatility. They should also weigh the governance trade-off of a 72.5% controlling holder. The family offers patient capital, but outside shareholders have limited influence.

This dossier is for information purposes and is not investment advice.*

--